Evidence map›Paper›PMID 14739490›Full record

ReviewEndocrine pathology2003

Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Hilde Dannenberg, Paul Komminoth, Winand N M Dinjens, Ernst Jan M Speel, Ronald R de Krijger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hilde DannenbergDepartment of Pathology, Josephine Nefkens Institute, Erasmus MC Rotterdam, The Netherlands.
Paul Komminoth
Winand N M Dinjens
Ernst Jan M Speel
Ronald R de Krijger

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pheochromocytomas and paragangliomas are neuroendocrine neoplasias of neural crest origin. Genetic mutations that are characterized in other human neoplasms are rarely seen in these tumors. About 10% of the patients with pheochromocytomas and paragangliomas present with a family history of von Hippel-Lindau disease (VHL), Multiple endocrine neoplasia type 2 (MEN2), one of the three familial paraganglioma syndromes (PGL; PGL1, PGL3, PGL4), or neurofibromatosis type 1 (NF1). In an even higher percentage, a genetic predisposition is involved in the development of these tumors. The genes of hereditary tumor syndromes such as the aforementioned ones are also ideal to study the molecular pathogenesis in the sporadic counterparts. Many studies have been undertaken to identify important secondary genetic events that contribute to the tumorigenesis of pheochromocytoma or paraganglioma, but a comprehensive review of these data is lacking. Recent findings of CGH and LOH studies provided new starting points to unravel the pathogenesis and progression of these tumors. This review presents an overview of our current understanding of the molecular pathogenesis of pheochromocytoma and paraganglioma.

Indexed as

Adrenal Gland NeoplasmsAnimalsBiomarkers, TumorHumansMultiple Endocrine Neoplasia Type 2aMultiple Endocrine Neoplasia Type 2bMutationNeurofibromatosis 1Oligonucleotide Array Sequence AnalysisParagangliomaPheochromocytomaProto-Oncogene ProteinsProto-Oncogene Proteins c-retReceptor Protein-Tyrosine Kinasesvon Hippel-Lindau DiseaseBiomarkers, TumorProto-Oncogene ProteinsProto-Oncogene Proteins c-retReceptor Protein-Tyrosine Kinases

Identifiers

PMID14739490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.